Find Lanifibranor manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 927961-18-0, Iva-337, Iva337, 28q8ag0pyl, Chembl4091374, Cpd1537
Molecular Formula
C19H15ClN2O4S2
Molecular Weight
434.9  g/mol
InChI Key
OQDQIFQRNZIEEJ-UHFFFAOYSA-N
FDA UNII
28Q8AG0PYL

Lanifibranor
Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).
1 2D Structure

Lanifibranor

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid
2.1.2 InChI
InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
2.1.3 InChI Key
OQDQIFQRNZIEEJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2
2.2 Other Identifiers
2.2.1 UNII
28Q8AG0PYL
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Iva337

2.3.2 Depositor-Supplied Synonyms

1. 927961-18-0

2. Iva-337

3. Iva337

4. 28q8ag0pyl

5. Chembl4091374

6. Cpd1537

7. 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic Acid

8. 1h-indole-2-butanoic Acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-

9. 5-chloro-1-((6-benzothiazolyl)sulfonyl)-1h-indole-2-butanoic Acid

10. 4-(1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic Acid

11. 4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1h-indol-2-yl)butanoic Acid

12. 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic Acid

13. Lanifbranor

14. Libfranor

15. Lanifbranor [inn]

16. Lanifibranor(iva-337)

17. Lanifibranor [inn]

18. Unii-28q8ag0pyl

19. Lanifibranor [who-dd]

20. Schembl3528615

21. Amy16813

22. Cmb96118

23. Ex-a1511

24. Bdbm50244350

25. S8770

26. Akos037649312

27. Db14801

28. Sb18746

29. Ac-31451

30. Bs-17993

31. Hy-104049

32. Cs-0027586

33. A903382

34. Q27896056

35. 1-(6-benzothiazolylsulfonyl)-5-chloro-1h-indole-2-butanoic Acid

36. Bjb

37. Iva-337; Iva 337;4-(1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic Acid;iva-337

2.4 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 434.9 g/mol
Molecular Formula C19H15ClN2O4S2
XLogP34.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass434.0161770 g/mol
Monoisotopic Mass434.0161770 g/mol
Topological Polar Surface Area126 Ų
Heavy Atom Count28
Formal Charge0
Complexity686
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty